BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36725331)

  • 1. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
    Muiser S; Imkamp K; Seigers D; Halbersma NJ; Vonk JM; Luijk BHD; Braunstahl GJ; van den Berg JW; Kroesen BJ; Kocks JWH; Heijink IH; Reddel HK; Kerstjens HAM; van den Berge M
    Thorax; 2023 May; 78(5):451-458. PubMed ID: 36725331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
    Aalbers R
    Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
    Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
    Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
    Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
    Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
    Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
    J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.
    Singh D; Garcia G; Maneechotesuwan K; Daley-Yates P; Irusen E; Aggarwal B; Boucot I; Berend N
    Adv Ther; 2022 May; 39(5):1895-1914. PubMed ID: 35284999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
    Davis JR; Kern DM; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    J Manag Care Spec Pharm; 2016 Mar; 22(3):293-304. PubMed ID: 27003559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?
    Brattsand R; Selroos O
    Pulm Pharmacol Ther; 2022 Dec; 77():102167. PubMed ID: 36180011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.